Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 4/20 | 0.74 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 3/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1365173 | 0.95 | NR1H2 (0.72) | ESR2NR1H2MAPK1ABHD6HDAC1 | |
| SCHEMBL2984097 | 0.92 | ESR2 (0.63) | ESR2NR1H2MAPK1ABHD6HDAC1 | |
| SCHEMBL2143962 | 0.89 | ESR2 (0.57) | ESR2NR1H2MAPK1ABHD6HDAC1 | |
| SCHEMBL450677 | 0.85 | ESR2 (1.00) | ESR2NR1H2MAPK1ABHD6HDAC1 | |
| SCHEMBL2056208 | 0.85 | ESR2 (0.76) | ESR2NR1H2MAPK1ABHD6HDAC1 | |
| SCHEMBL29590844 | 0.85 | ESR2 (1.00) | ESR2NR1H2MAPK1ABHD6HDAC1 | |
| SCHEMBL2095898 | 0.85 | ESR2 (0.76) | ESR2NR1H2MAPK1ABHD6HDAC1 | |
| SCHEMBL31621670 | 0.84 | ESR2 (0.78) | ESR2NR1H2MAPK1ABHD6HDAC1 | |
| SCHEMBL19684692 | 0.84 | ESR2 (0.78) | ESR2NR1H2MAPK1ABHD6HDAC1 | |
| SCHEMBL31067462 | 0.84 | ESR2 (0.74) | ESR2NR1H2MAPK1ABHD6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069327-B1 | NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-20120010185-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-12 | — | — | US | disclosed |
| US-8067590-B2 | Melanin-concentrating hormone (MCH) receptor antagonists; treating obesity, eating disorders, affective disorders, drug dependency; compounds are amino-functional pyridazin-3-one, 1H-pyridin-2-one or 3H-pyrimidin-4-one | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-29 | — | — | US | disclosed |
| EP-2383259-A1 | New pyridone derivatives with MCH antagonistic activity and medicaments comprising these compounds | Boehringer Ingelheim International GmbH (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| WO-2009103478-A1 | PYRIDONE AND PYRIDAZINONE DERIVATIVES AS MCH ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-27 | — | — | WO | disclosed |
| US-20080255083-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010185-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | MCHR1, MCHR2, GPR119 | ESR2 1432/4885NR1H2 1613/4885MAPK1 2194/4885 |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | MCHR1, MCHR2, MC5R | ESR2 699/4885NR1H2 842/4885MAPK1 2442/4885 |
| US-20080255083-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | MCHR1, MCHR2, GPR119 | ESR2 1432/4885NR1H2 1613/4885MAPK1 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.